Understanding your type of prostate cancer

When it comes to prostate cancer treatment, it helps to understand your type of prostate cancer and how ERLEADA® can help. If your doctor has prescribed ERLEADA® it’s because you have one of the types of prostate cancer described below.

What is metastatic castration-sensitive prostate cancer (mCSPC)?

Prostate cancer that HAS SPREAD to other parts of the body and STILL RESPONDS to a medical or surgical treatment that lowers testosterone. This is called metastatic castration-sensitive prostate cancer, or mCSPC.

The most common sites where prostate cancer can spread are bones, liver, and lungs.

Chart overviewing what metastatic castration-sensitive prostate cancer (mCSPC) is

What is non-metastatic castration-resistant prostate cancer (nmCRPC)?

Prostate cancer that HAS NOT SPREAD to other parts of the body and NO LONGER responds to a medical or surgical treatment that lowers testosterone. This is called non-metastatic castration-resistant prostate cancer, or nmCRPC.

Chart overviewing what non-metastatic castration-resistant prostate cancer (nmCRPC) is
An anatomical diagram showing the location of the prostate

View the ERLEADA® Patient Brochure

Learn more about ERLEADA® and what to expect from treatment, as well as information about available savings and support.

View English Brochure
View Spanish Brochure

Learn more about prostate cancer

Black men and prostate cancer: prostate and total health are tied together

Being proactive about our health is the best way to influence our care, and it requires speaking up for ourselves when necessary.

Ready to Talk That Talk

My Prostate Cancer Roadmap

Put yourself in the driver’s seat to managing prostate cancer with information and resources available here.

Create Your Roadmap

Why ERLEADA®